Fentanyl

Generic Name: Fentanyl

Brand Names: Abstral, Actiq, Duragesic, Effentora, Fentora, Instanyl, Lazanda, Sublimaze, Subsys, PecFent

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₈N_₂O

CAS Number: 437-38-7

Unique Ingredient Identifier: UF599785JZ

Background: Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia. Fentanyl is related to other opioids like morphine and oxycodone.

Fentanyl's high potency has also made it a common adulterant in illicit drugs, especially heroin. In 2017, 47600 overdose deaths in the United States involved some opioid (over 2/3 of all overdose deaths). Opioid overdoses kill an average of 11 Canadians daily.

Fentanyl was FDA approved in 1968.

Indication: Fentanyl intravenous or intramuscular injections are indicated for short term analgesia during induction, maintenance, and recovery from general or regional anesthesia. These injections are also used with a neuroleptic for premedication, induction, and as an adjunct to maintenance of anesthesia. Finally, fentanyl intravenous or intramuscular injections are used with oxygen for anesthesia in high risk patients.

Fentanyl sublingual tablets, transmucosal lozenges, buccal tablets, sublingual sprays, transdermal systems, and nasal sprays are indicated for the management of breakthrough pain in opioid tolerant cancer patients who require around the clock pain management.

Associated Conditions: Cancer Related Pain (Breakthrough Pain), Severe, Chronic Pain

Associated Therapies: Anesthetic premedication therapy, Anesthetics Agent, General Anesthesia, Induction of anesthesia therapy, Maintenance of anesthesia therapy, Regional Anesthesia therapy

Clinical Trials

Treatment of Procedural Pain Associated With Turning in Patients With Mechanical Ventilation

Phase 4

Completed

Conditions: Critical Illness
Pain

Interventions: Other: Placebo
Drug: Fentanyl

First Posted Date: 2013-09-25

Last Posted Date: 2013-09-30

Lead Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Target Recruit Count: 75

Registration Number: NCT01950000

Locations: 🇪🇸
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain

Completed

Conditions: Neuropathic Pain
Tumor
Breakthrough Cancer Pain
Cancer Pain

Interventions: Drug: Morphine
Drug: Fentanyl
Drug: Methadone
Drug: Buprenorphine
Drug: Oxycodone
Drug: Hydromorphone
Drug: Tapentadol

First Posted Date: 2013-09-19

Last Posted Date: 2016-04-14

Lead Sponsor: Mario Negri Institute for Pharmacological Research

Target Recruit Count: 150

Registration Number: NCT01946555

Locations: 🇮🇹
A.O. Universitaria Parma, Parma, Italia, Italy
🇮🇹
Ospedale di Piacenza, Piacenza, Italy
🇮🇹
Ospedale Magati, Scandiano, Italia, Italy

and more 8 locations

Remimazolam Phase II Cardiac Anesthesia Study

Phase 2

Completed

Conditions: General Anesthesia

Interventions: Drug: Propofol
Drug: Remimazolam
Drug: Remifentanil
Drug: Sevoflurane
Drug: Fentanyl
Drug: Rocuronium

First Posted Date: 2013-09-10

Last Posted Date: 2020-01-18

Lead Sponsor: Paion UK Ltd.

Target Recruit Count: 90

Registration Number: NCT01937767

Locations: 🇩🇪
Herzzentrum Leipzig GmbH, Leipzig, Germany

Observational Registry Study of Quality of Life When Treating BTcP With Abstral

Completed

Conditions: Quality of Life
Breakthrough Cancer Pain

Interventions: Drug: Fentanyl

First Posted Date: 2013-09-06

Last Posted Date: 2015-11-05

Lead Sponsor: Galena Biopharma, Inc.

Target Recruit Count: 164

Registration Number: NCT01936636

Locations: 🇺🇸
Florida Cancer Care, Plantation, Florida, United States
🇺🇸
Coastal Pain Research, Carlsbad, California, United States
🇺🇸
Navajo Road Pain Management Center, El Cajon, California, United States

and more 32 locations